Cardiol Therapeutics to Webcast Live at on June 4  

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on


OAKVILLE, Ontario, June 3, 2019 /PRNewswire/ -- Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, announces that David Elsley, President and CEO of Cardiol, will present live at on June 4th.

DATE: Tuesday, June 4th 

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at

About Virtual Investor Conferences

Virtual Investor Conferences is the leading proprietary investor conference series that provides an interactive forum for publicly traded     companies to meet and present directly with investors. A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a leader in the research and commercial development of pharmaceutical CBD products and targeted therapies for inflammatory disease. The Company is leveraging its expertise in pharmaceutical CBD to develop ultra-pure CBD products for commercialization in the billion dollar market for medicinal cannabinoids in Canada, with a view to expanding into Latin America and Europe, and utilizing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure. Heart failure is a leading cause of death and hospitalization, with associated healthcare costs exceeding $30 billion annually in the U.S. alone. For further information about Cardiol, please visit the Company's website at

Cision View original content:


In This Story